The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations

Pituitary neuroendocrine tumors (PitNETs) are divided into multiple histological subtypes, which determine their clinical and biological variable behavior. Despite their benign evolution, in some cases, prolactin (PRL) and growth hormone (GH)-secreting PitNETs may have aggressive behavior. In this s...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 24; no. 22; p. 16162
Main Authors Dumitriu-Stan, Roxana-Ioana, Burcea, Iulia-Florentina, Nastase, Valeria Nicoleta, Ceaușu, Raluca Amalia, Dumitrascu, Anda, Cocosila, Laurentiu Catalin, Bastian, Alexandra, Zurac, Sabina, Raica, Marius, Poiana, Catalina
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.11.2023
Subjects
Online AccessGet full text
ISSN1422-0067
1661-6596
1422-0067
DOI10.3390/ijms242216162

Cover

Abstract Pituitary neuroendocrine tumors (PitNETs) are divided into multiple histological subtypes, which determine their clinical and biological variable behavior. Despite their benign evolution, in some cases, prolactin (PRL) and growth hormone (GH)-secreting PitNETs may have aggressive behavior. In this study, we investigated the potential predictive role of ER∝, alongside the clinicopathological classification of PitNETs (tumor diameter, tumor type, and tumor grade). A retrospective study was conducted with 32 consecutive cases of PRL- and mixed GH- and PRL-secreting PitNETs (5 patients with prolactinomas and 27 with acromegaly, among them, 7 patients with GH- and PRL- co-secretion) who underwent transsphenoidal intervention. Tumor specimens were histologically and immunohistochemical examined: anterior pituitary hormones, ki-67 labeling index, CAM 5.2, and ER∝; ER∝ expression was correlated with basal PRL levels at diagnosis (rho = 0.60, p < 0.01) and postoperative PRL levels (rho = 0.58, p < 0.001). In our study, the ER∝ intensity score was lower in female patients. Postoperative maximal tumor diameter correlated with Knosp grade (p = 0.02); CAM 5.2 pattern (densely/sparsely granulated/mixed densely and sparsely granulated) was correlated with postoperative PRL level (p = 0.002), and with ki-67 (p < 0.001). The IGF1 level at diagnosis was correlated with the postoperative GH nadir value in the oral glucose tolerance test (OGTT) (rho = 0.52, p < 0.05). Also, basal PRL level at diagnosis was correlated with postoperative tumor diameter (p = 0.63, p < 0.001). At univariate logistic regression, GH nadir in OGTT test at diagnostic, IGF1, gender, and invasion were independent predictors of remission for mixed GH- and PRL-secreting Pit-NETs; ER∝ can be used as a prognostic marker and loss of ER∝ expression should be considered a sign of lower differentiation and a likely indicator of poor prognosis. A sex-related difference can be considered in the evolution and prognosis of these tumors, but further studies are needed to confirm this hypothesis.
AbstractList Pituitary neuroendocrine tumors (PitNETs) are divided into multiple histological subtypes, which determine their clinical and biological variable behavior. Despite their benign evolution, in some cases, prolactin (PRL) and growth hormone (GH)-secreting PitNETs may have aggressive behavior. In this study, we investigated the potential predictive role of ER∝, alongside the clinicopathological classification of PitNETs (tumor diameter, tumor type, and tumor grade). A retrospective study was conducted with 32 consecutive cases of PRL- and mixed GH- and PRL-secreting PitNETs (5 patients with prolactinomas and 27 with acromegaly, among them, 7 patients with GH- and PRL- co-secretion) who underwent transsphenoidal intervention. Tumor specimens were histologically and immunohistochemical examined: anterior pituitary hormones, ki-67 labeling index, CAM 5.2, and ER∝; ER∝ expression was correlated with basal PRL levels at diagnosis (rho = 0.60, p < 0.01) and postoperative PRL levels (rho = 0.58, p < 0.001). In our study, the ER∝ intensity score was lower in female patients. Postoperative maximal tumor diameter correlated with Knosp grade (p = 0.02); CAM 5.2 pattern (densely/sparsely granulated/mixed densely and sparsely granulated) was correlated with postoperative PRL level (p = 0.002), and with ki-67 (p < 0.001). The IGF1 level at diagnosis was correlated with the postoperative GH nadir value in the oral glucose tolerance test (OGTT) (rho = 0.52, p < 0.05). Also, basal PRL level at diagnosis was correlated with postoperative tumor diameter (p = 0.63, p < 0.001). At univariate logistic regression, GH nadir in OGTT test at diagnostic, IGF1, gender, and invasion were independent predictors of remission for mixed GH- and PRL-secreting Pit-NETs; ER∝ can be used as a prognostic marker and loss of ER∝ expression should be considered a sign of lower differentiation and a likely indicator of poor prognosis. A sex-related difference can be considered in the evolution and prognosis of these tumors, but further studies are needed to confirm this hypothesis.Pituitary neuroendocrine tumors (PitNETs) are divided into multiple histological subtypes, which determine their clinical and biological variable behavior. Despite their benign evolution, in some cases, prolactin (PRL) and growth hormone (GH)-secreting PitNETs may have aggressive behavior. In this study, we investigated the potential predictive role of ER∝, alongside the clinicopathological classification of PitNETs (tumor diameter, tumor type, and tumor grade). A retrospective study was conducted with 32 consecutive cases of PRL- and mixed GH- and PRL-secreting PitNETs (5 patients with prolactinomas and 27 with acromegaly, among them, 7 patients with GH- and PRL- co-secretion) who underwent transsphenoidal intervention. Tumor specimens were histologically and immunohistochemical examined: anterior pituitary hormones, ki-67 labeling index, CAM 5.2, and ER∝; ER∝ expression was correlated with basal PRL levels at diagnosis (rho = 0.60, p < 0.01) and postoperative PRL levels (rho = 0.58, p < 0.001). In our study, the ER∝ intensity score was lower in female patients. Postoperative maximal tumor diameter correlated with Knosp grade (p = 0.02); CAM 5.2 pattern (densely/sparsely granulated/mixed densely and sparsely granulated) was correlated with postoperative PRL level (p = 0.002), and with ki-67 (p < 0.001). The IGF1 level at diagnosis was correlated with the postoperative GH nadir value in the oral glucose tolerance test (OGTT) (rho = 0.52, p < 0.05). Also, basal PRL level at diagnosis was correlated with postoperative tumor diameter (p = 0.63, p < 0.001). At univariate logistic regression, GH nadir in OGTT test at diagnostic, IGF1, gender, and invasion were independent predictors of remission for mixed GH- and PRL-secreting Pit-NETs; ER∝ can be used as a prognostic marker and loss of ER∝ expression should be considered a sign of lower differentiation and a likely indicator of poor prognosis. A sex-related difference can be considered in the evolution and prognosis of these tumors, but further studies are needed to confirm this hypothesis.
Pituitary neuroendocrine tumors (PitNETs) are divided into multiple histological subtypes, which determine their clinical and biological variable behavior. Despite their benign evolution, in some cases, prolactin (PRL) and growth hormone (GH)-secreting PitNETs may have aggressive behavior. In this study, we investigated the potential predictive role of ER∝, alongside the clinicopathological classification of PitNETs (tumor diameter, tumor type, and tumor grade). A retrospective study was conducted with 32 consecutive cases of PRL- and mixed GH- and PRL-secreting PitNETs (5 patients with prolactinomas and 27 with acromegaly, among them, 7 patients with GH- and PRL- co-secretion) who underwent transsphenoidal intervention. Tumor specimens were histologically and immunohistochemical examined: anterior pituitary hormones, ki-67 labeling index, CAM 5.2, and ER∝; ER∝ expression was correlated with basal PRL levels at diagnosis (rho = 0.60, p < 0.01) and postoperative PRL levels (rho = 0.58, p < 0.001). In our study, the ER∝ intensity score was lower in female patients. Postoperative maximal tumor diameter correlated with Knosp grade (p = 0.02); CAM 5.2 pattern (densely/sparsely granulated/mixed densely and sparsely granulated) was correlated with postoperative PRL level (p = 0.002), and with ki-67 (p < 0.001). The IGF1 level at diagnosis was correlated with the postoperative GH nadir value in the oral glucose tolerance test (OGTT) (rho = 0.52, p < 0.05). Also, basal PRL level at diagnosis was correlated with postoperative tumor diameter (p = 0.63, p < 0.001). At univariate logistic regression, GH nadir in OGTT test at diagnostic, IGF1, gender, and invasion were independent predictors of remission for mixed GH- and PRL-secreting Pit-NETs; ER∝ can be used as a prognostic marker and loss of ER∝ expression should be considered a sign of lower differentiation and a likely indicator of poor prognosis. A sex-related difference can be considered in the evolution and prognosis of these tumors, but further studies are needed to confirm this hypothesis.
Audience Academic
Author Zurac, Sabina
Bastian, Alexandra
Nastase, Valeria Nicoleta
Cocosila, Laurentiu Catalin
Raica, Marius
Ceaușu, Raluca Amalia
Dumitriu-Stan, Roxana-Ioana
Burcea, Iulia-Florentina
Dumitrascu, Anda
Poiana, Catalina
Author_xml – sequence: 1
  givenname: Roxana-Ioana
  orcidid: 0000-0003-4568-2714
  surname: Dumitriu-Stan
  fullname: Dumitriu-Stan, Roxana-Ioana
– sequence: 2
  givenname: Iulia-Florentina
  surname: Burcea
  fullname: Burcea, Iulia-Florentina
– sequence: 3
  givenname: Valeria Nicoleta
  surname: Nastase
  fullname: Nastase, Valeria Nicoleta
– sequence: 4
  givenname: Raluca Amalia
  orcidid: 0000-0002-0067-8247
  surname: Ceaușu
  fullname: Ceaușu, Raluca Amalia
– sequence: 5
  givenname: Anda
  surname: Dumitrascu
  fullname: Dumitrascu, Anda
– sequence: 6
  givenname: Laurentiu Catalin
  surname: Cocosila
  fullname: Cocosila, Laurentiu Catalin
– sequence: 7
  givenname: Alexandra
  surname: Bastian
  fullname: Bastian, Alexandra
– sequence: 8
  givenname: Sabina
  surname: Zurac
  fullname: Zurac, Sabina
– sequence: 9
  givenname: Marius
  surname: Raica
  fullname: Raica, Marius
– sequence: 10
  givenname: Catalina
  surname: Poiana
  fullname: Poiana, Catalina
BookMark eNp9kM9qGzEQxpeSQJO0x94FvfSyqf55tdtbME5SMK1J3F6FVjtyZGTJlbSUvEFfoi_XJ6kcF1IHEgSjYeb7DTPfaXXkg4eqekfwOWMd_mjXm0Q5paQhDX1VnZCS1xg34ui__HV1mtIaY8ropDupzPIO0HflRkDBoNnNn1-_kfUol-oihpUPyaZd5-q6RsoPaHEzr29BR8jWr9DC5i-zZfqEps56q8NW5bvgwspq5dA0xAhOZRt8elMdG-USvP33n1XfLmfL6XU9_3r1eXoxrzXHPNcC2k50RPSknzBMqRpUB0oPnGCgmE4aYXqghmPS9txQ3Det6odGK4Ib1k0YO6vO93NHv1X3P5VzchvtRsV7SbDcuSQPXCrAhz2wjeHHCCnLjU0anFMewpgkbTvWclZCkb5_Il2HMfpyzoMKC8o4eVStlANpvQk5Kr0bKi-E4IwSysTjngeq8gbYFB89GFvqBwDbAzqGlCIYqW1-8LaA1j17Xf2EetmNv39qsXQ
CitedBy_id crossref_primary_10_1210_clinem_dgae615
crossref_primary_10_1007_s12020_024_04130_6
Cites_doi 10.1007/s11102-019-00982-8
10.1172/JCI0214264
10.1186/s13063-021-05604-y
10.1210/jendso/bvaa157
10.1159/000499382
10.1016/0010-7824(83)90057-4
10.1016/j.beem.2019.101290
10.1007/s00701-005-0498-2
10.1023/A:1011412028660
10.1111/cen.12242
10.3390/ijms21062024
10.1210/jc.2009-1191
10.3389/fmed.2015.00054
10.1007/s12020-019-02029-1
10.1210/jcem.86.2.7226
10.1210/jc.2013-3054
10.1007/s00234-015-1519-3
10.1038/s41598-023-42157-3
10.1046/j.0007-1331.2001.00744.x
10.4132/jptm.2016.06.30
10.1007/s11102-016-0723-4
10.1530/EJE-14-0990
10.1210/jc.2010-1692
10.1007/BF01833337
10.2174/1871530323666230511104045
10.1007/s11102-012-0426-4
10.1038/s41574-018-0058-5
10.3389/fendo.2021.684055
10.1530/EJE-07-0806
10.1007/s12022-022-09703-7
10.3389/fendo.2018.00706
10.1210/jc.2014-2700
10.1016/j.mce.2005.04.008
10.1016/j.ghir.2020.101337
10.3389/fendo.2021.793337
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
ADTOC
UNPAY
DOI 10.3390/ijms242216162
DatabaseName CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Research Library
Research Library (Corporate)
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1422-0067
ExternalDocumentID 10.3390/ijms242216162
A774321237
10_3390_ijms242216162
GeographicLocations Romania
GeographicLocations_xml – name: Romania
GroupedDBID ---
29J
2WC
53G
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
ESTFP
ESX
F5P
FRP
FYUFA
GNUQQ
GUQSH
GX1
HH5
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M2O
M48
MODMG
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RNS
RPM
TR2
TUS
UKHRP
~8M
ALIPV
PMFND
3V.
7XB
8FK
K9.
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
ADRAZ
ADTOC
C1A
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c404t-7e897917b1b53022ada9eacd410e202567fbe2f4018b4f20b68abd6ca10639533
IEDL.DBID M48
ISSN 1422-0067
1661-6596
IngestDate Tue Aug 19 23:21:52 EDT 2025
Mon Sep 08 14:50:40 EDT 2025
Fri Jul 25 21:41:43 EDT 2025
Tue Jun 17 22:19:14 EDT 2025
Tue Jun 10 21:20:32 EDT 2025
Wed Oct 01 03:04:05 EDT 2025
Thu Apr 24 23:03:48 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 22
Language English
License https://creativecommons.org/licenses/by/4.0
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c404t-7e897917b1b53022ada9eacd410e202567fbe2f4018b4f20b68abd6ca10639533
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0067-8247
0000-0003-4568-2714
OpenAccessLink https://www.proquest.com/docview/2893072341?pq-origsite=%requestingapplication%
PQID 2893072341
PQPubID 2032341
ParticipantIDs unpaywall_primary_10_3390_ijms242216162
proquest_miscellaneous_2893843938
proquest_journals_2893072341
gale_infotracmisc_A774321237
gale_infotracacademiconefile_A774321237
crossref_citationtrail_10_3390_ijms242216162
crossref_primary_10_3390_ijms242216162
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-11-01
PublicationDateYYYYMMDD 2023-11-01
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle International journal of molecular sciences
PublicationYear 2023
Publisher MDPI AG
Publisher_xml – name: MDPI AG
References Ozturk (ref_34) 2020; 55
McKevitt (ref_35) 2023; 13
Melmed (ref_17) 2011; 2
Roche (ref_24) 2015; 2
Kansra (ref_27) 2005; 1–2
Katznelson (ref_16) 2014; 11
Wierinckx (ref_8) 2018; 9
Melmed (ref_13) 2018; 14
ref_12
ref_10
Kim (ref_42) 2016; 6
Pollak (ref_36) 1992; 22
Raverot (ref_23) 2010; 4
Asa (ref_43) 2022; 33
Chanson (ref_1) 2019; 33
Chen (ref_40) 2021; 12
Hulting (ref_29) 1983; 1
Besser (ref_2) 1993; 129
Trouillas (ref_18) 2019; 1
Zandbergen (ref_14) 2021; 1
Moraes (ref_3) 2013; 79
Monsalves (ref_41) 2014; 99
Bima (ref_11) 2021; 12
Cozzi (ref_4) 2023; 23
Delgrange (ref_19) 2015; 172
Delgrange (ref_20) 2013; 1
Karavitaki (ref_26) 2007; 2
Heaney (ref_9) 2002; 109
Klein (ref_15) 2001; 86
Shimon (ref_37) 2012; 15
Kreutz (ref_22) 2015; 7
Jiang (ref_5) 2019; 66
Shimon (ref_21) 2016; 4
Fusco (ref_33) 2008; 5
Manoranjan (ref_6) 2010; 30
Shupnik (ref_28) 2002; 2
Orrego (ref_31) 2000; 3
Jaquet (ref_32) 1999; 9
Bazuhair (ref_25) 2023; 15
Marroni (ref_38) 2004; 3
ref_7
Delgrange (ref_30) 2005; 7
Pappy (ref_39) 2019; 22
References_xml – volume: 22
  start-page: 520
  year: 2019
  ident: ref_39
  article-title: Predictive modeling for pituitary adenomas: Single center experience in 501 consecutive patients
  publication-title: Pituitary
  doi: 10.1007/s11102-019-00982-8
– volume: 109
  start-page: 277
  year: 2002
  ident: ref_9
  article-title: Functional role of estrogen in pituitary tumor pathogenesis
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI0214264
– volume: 1
  start-page: 653
  year: 2021
  ident: ref_14
  article-title: The PRolaCT studies—A study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma
  publication-title: Trials
  doi: 10.1186/s13063-021-05604-y
– ident: ref_10
  doi: 10.1210/jendso/bvaa157
– volume: 1
  start-page: 70
  year: 2019
  ident: ref_18
  article-title: Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours
  publication-title: Neuroendocrinology
  doi: 10.1159/000499382
– volume: 1
  start-page: 69
  year: 1983
  ident: ref_29
  article-title: Oral contraceptive steroids do not promote the development or growth of prolactinomas
  publication-title: Contraception
  doi: 10.1016/0010-7824(83)90057-4
– volume: 33
  start-page: 1012
  year: 2019
  ident: ref_1
  article-title: The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new
  publication-title: Best Pract. Res. Clin. Endocrinol. Metab.
  doi: 10.1016/j.beem.2019.101290
– volume: 7
  start-page: 751
  year: 2005
  ident: ref_30
  article-title: Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance
  publication-title: Acta Neurochir.
  doi: 10.1007/s00701-005-0498-2
– volume: 3
  start-page: 189
  year: 2000
  ident: ref_31
  article-title: Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine
  publication-title: Pituitary
  doi: 10.1023/A:1011412028660
– volume: 79
  start-page: 447
  year: 2013
  ident: ref_3
  article-title: Giant prolactinomas: The therapeutic approach
  publication-title: Clin. Endocrinol.
  doi: 10.1111/cen.12242
– ident: ref_7
  doi: 10.3390/ijms21062024
– volume: 4
  start-page: 1708
  year: 2010
  ident: ref_23
  article-title: Prognostic factors in prolactin pituitary tumors: Clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2009-1191
– volume: 2
  start-page: 54
  year: 2015
  ident: ref_24
  article-title: Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors
  publication-title: Front. Med.
  doi: 10.3389/fmed.2015.00054
– volume: 66
  start-page: 310
  year: 2019
  ident: ref_5
  article-title: Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: A retrospective study with long-term follow-up
  publication-title: Endocrine
  doi: 10.1007/s12020-019-02029-1
– volume: 86
  start-page: 656
  year: 2001
  ident: ref_15
  article-title: Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jcem.86.2.7226
– volume: 99
  start-page: 1330
  year: 2014
  ident: ref_41
  article-title: Growth Patterns of Pituitary Adenomas and Histopathological Correlates
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2013-3054
– volume: 7
  start-page: 679
  year: 2015
  ident: ref_22
  article-title: Intensity of prolactinoma on T2-weighted magnetic resonance imaging: Towards another gender difference
  publication-title: Neuroradiology
  doi: 10.1007/s00234-015-1519-3
– volume: 9
  start-page: 3268
  year: 1999
  ident: ref_32
  article-title: Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas
  publication-title: J. Clin. Endocrinol. Metab.
– volume: 13
  start-page: 15409
  year: 2023
  ident: ref_35
  article-title: Supervised machine learning to validate a novel scoring system for the prediction of disease remission of functional pituitary adenomas following transsphenoidal surgery
  publication-title: Sci Rep.
  doi: 10.1038/s41598-023-42157-3
– volume: 30
  start-page: 2897
  year: 2010
  ident: ref_6
  article-title: Estrogen receptors alpha and beta immunohistochemical expression: Clinicopathological correlations in pituitary adenomas
  publication-title: Anticancer Res.
– volume: 2
  start-page: 85
  year: 2002
  ident: ref_28
  article-title: Oestrogen receptors, receptor variants and oestrogen actions in the hypothalamic-pituitary axis
  publication-title: J. Neuroendocrinol.
  doi: 10.1046/j.0007-1331.2001.00744.x
– volume: 6
  start-page: 419
  year: 2016
  ident: ref_42
  article-title: The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence
  publication-title: J. Pathol. Transl. Med.
  doi: 10.4132/jptm.2016.06.30
– volume: 4
  start-page: 429
  year: 2016
  ident: ref_21
  article-title: Giant prolactinomas larger than 60 mm in size: A cohort of massive and aggressive prolactin-secreting pituitary adenomas
  publication-title: Pituitary
  doi: 10.1007/s11102-016-0723-4
– volume: 172
  start-page: 791
  year: 2015
  ident: ref_19
  article-title: Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth
  publication-title: Eur. J. Endocrinol.
  doi: 10.1530/EJE-14-0990
– ident: ref_12
– volume: 1
  start-page: 31
  year: 2013
  ident: ref_20
  article-title: Giant prolactinomas in women
  publication-title: Eur. J. Endocrinol.
– volume: 2
  start-page: 273
  year: 2011
  ident: ref_17
  article-title: Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2010-1692
– volume: 129
  start-page: 27
  year: 1993
  ident: ref_2
  article-title: Criteria for medical as opposed to surgical treatment of prolactinomas
  publication-title: Acta Endocrinol.
– volume: 3
  start-page: 119
  year: 2004
  ident: ref_38
  article-title: Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication
  publication-title: Neuroendocrinology
– volume: 22
  start-page: 91
  year: 1992
  ident: ref_36
  article-title: Tamoxifen reduces serum insulin-like growth factor I (IGF-I)
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/BF01833337
– volume: 2
  start-page: 143
  year: 2007
  ident: ref_26
  article-title: What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics
  publication-title: Eur. J. Endocrinol.
– volume: 23
  start-page: 1459
  year: 2023
  ident: ref_4
  article-title: Italian Guidelines for the Management of Prolactinomas
  publication-title: Endocr. Metab. Immune Disord. Drug Targets
  doi: 10.2174/1871530323666230511104045
– volume: 15
  start-page: 601
  year: 2012
  ident: ref_37
  article-title: Estrogen treatment for acromegaly
  publication-title: Pituitary
  doi: 10.1007/s11102-012-0426-4
– volume: 14
  start-page: 552
  year: 2018
  ident: ref_13
  article-title: A Consensus Statement on acromegaly therapeutic outcomes
  publication-title: Nat. Rev. Endocrinol.
  doi: 10.1038/s41574-018-0058-5
– volume: 15
  start-page: e35171
  year: 2023
  ident: ref_25
  article-title: Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review
  publication-title: Cureus.
– volume: 12
  start-page: 684055
  year: 2021
  ident: ref_11
  article-title: Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results from a Pilot Study
  publication-title: Front. Endocrinol.
  doi: 10.3389/fendo.2021.684055
– volume: 5
  start-page: 595
  year: 2008
  ident: ref_33
  article-title: Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas
  publication-title: Eur. J. Endocrinol.
  doi: 10.1530/EJE-07-0806
– volume: 33
  start-page: 6
  year: 2022
  ident: ref_43
  article-title: Overview of the 2022 WHO Classification of Pituitary Tumors
  publication-title: Endocr. Pathol.
  doi: 10.1007/s12022-022-09703-7
– volume: 9
  start-page: 706
  year: 2018
  ident: ref_8
  article-title: Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated with a Specific Gene-Expression Signature and Genome Instability
  publication-title: Front. Endocrinol.
  doi: 10.3389/fendo.2018.00706
– volume: 11
  start-page: 3933
  year: 2014
  ident: ref_16
  article-title: Acromegaly: An endocrine society clinical practice guideline
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2014-2700
– volume: 1–2
  start-page: 27
  year: 2005
  ident: ref_27
  article-title: Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release
  publication-title: Mol. Cell. Endocrinol.
  doi: 10.1016/j.mce.2005.04.008
– volume: 55
  start-page: 101337
  year: 2020
  ident: ref_34
  article-title: The significance of estrogen receptors in acromegaly: Are they useful as predictors of prognosis and therapy regimen?
  publication-title: Growth Horm. IGF Res.
  doi: 10.1016/j.ghir.2020.101337
– volume: 12
  start-page: 793337
  year: 2021
  ident: ref_40
  article-title: Analysis of Related Factors of Tumor Recurrence or Progression After Transnasal Sphenoidal Surgical Treatment of Large and Giant Pituitary Adenomas and Establish a Nomogram to Predict Tumor Prognosis
  publication-title: Front. Endocrinol.
  doi: 10.3389/fendo.2021.793337
SSID ssj0023259
Score 2.4196036
Snippet Pituitary neuroendocrine tumors (PitNETs) are divided into multiple histological subtypes, which determine their clinical and biological variable behavior....
SourceID unpaywall
proquest
gale
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 16162
SubjectTerms Cabergoline
Cancer
Cell growth
Clinical medicine
Dopamine
Estrogens
Females
Gender differences
Glucose tolerance tests
Growth factors
Health aspects
Hyperplasia
Kinases
Lanreotide
Medical colleges
Patients
Pituitary gland
Prognosis
Prolactin
Somatotropin
Surgery
Transcription factors
Tumorigenesis
Tumors
Women
SummonAdditionalLinks – databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3bThsxEB1RECp9QFxFykVGqtqXWmS9d14QQglRBSiiUPG2sr22FBR2UzZRxR_wE_wcX8JM1gkEqbza3l3LM5454x3PAfiGGEHbhO5t5VLywIa4peIg536ijNKWGui84_wi6lwHv27CG3fgVrm0yolNHBvqvNR0Rn6AgQGqo0CjezT4y4k1iv6uOgqNT7DgCdQkuinePp0GXL4Yk6V56IN4FKZRXWPTxzD_oHd7V6F3Egh4IjHjk95b5i_weVQM5MM_2e-_cT3tFVh2mJEd10JehTlTrMFizSL5sA4WRc3-yP7IsNKy1uXz4xPrFQyRHevel5RI16uo57TDmSxy1r08478JLVLGM-v2hhetq-qQ1RVCS6IonhhEdkLcHS5bbgOu262rkw539AlcB81gyGOTpDFGY8pTRA0kZC5TNLN54DWNIKgTW2WExQArUYEVTRUlUuWRlh7BFoSBmzBflIXZAmYClYbYHlqMv3SYpLIpQ0X5sSIKfWkb8HOygJl2tcWJ4qKfYYxB653NrHcDvk-HD-qiGv8b-IOkkdFmw_dp6e4M4KyobFV2jODVJ-cbN2BnZiRuEj3bPZFn5jZplb2qVAP2p930JCWeFaYc1WMSBG1-gnOZ6sHHs_768ce2YYk46-sLjTswP7wfmV1ENkO1N1bfFxjV9EI
  priority: 102
  providerName: ProQuest
Title The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations
URI https://www.proquest.com/docview/2893072341
https://www.proquest.com/docview/2893843938
https://www.mdpi.com/1422-0067/24/22/16162/pdf?version=1699607040
UnpaywallVersion publishedVersion
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFSB
  databaseName: Free Full-Text Journals in Chemistry
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: HH5
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://abc-chemistry.org/
  providerName: ABC ChemistRy
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: KQ8
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: KQ8
  dateStart: 20070101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: ABDBF
  dateStart: 20081201
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: DIK
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central (Free e-resource, activated by CARLI)
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: RPM
  dateStart: 20070101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: 7X7
  dateStart: 20000301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: BENPR
  dateStart: 20000301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Technology Collection
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: 8FG
  dateStart: 20000301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/technologycollection1
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Open Access Journals
  customDbUrl:
  eissn: 1422-0067
  dateEnd: 20250831
  omitProxy: true
  ssIdentifier: ssj0023259
  issn: 1661-6596
  databaseCode: M48
  dateStart: 20070101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3bahsxEB0Sh5D2oaS5EKeOUaC0L1Vjr7VeuVBKEnyhNMa4dvHbIu1K4LLZdXyh9R_0J_pz-ZLMZHdN3DahL_sgaYWQRjNnpNEcgNeIEQIr6d1WqBQX1sUt5YmQ16Q2OrBUQOcdV916Zyg-j9zRBuRxutkEzv7p2hGf1HAavf95s_yEG_4jeZzosp-Nv1_P0NI4CF5wZ09uOHFK0d1rRrCxCVtopxyS-SuxumNAKHFPpUaHIJyUdpqB8-8e1yzWn3r7Oews4ola_lBR9MAwtXbhRYYo2XkqAi9hw8R7sJ1yTC73waIgsG8qWhiWWNbs3_76zcYxQ9zHetOEwuzGM6ppdzhTcch6_S_8K2FJiodmvfG82xzMPrA0f2hCBMa5umSXxOyRxdIdwLDVHFx2eEauwANREXPuGdnw0FfTVU3EQY4KVQOVcCiqFeMQEPKsNo5F90tqYZ2Krkulw3qgqgRqECQeQiFOYnMEzAjdcLHcteidBa5sqIpyNUXPOnW3pmwR3uUT6AdZ5nEiwIh89EBovv21-S7Cm1XzSZpy47GGb2k1fBIO7C9Q2YsCHBUltfLPEdrWyDR7RSittcQtFKxX5-vp5xLooyeK-s9BK1-E01U1_UlhabFJFmkbiZCuJnEsKzl4etTH_9HbK3hGtPbpm8cSFObThTlB8DPXZdj0Rh5-Zatdhq2LZrfXL5M5csv30n0HockFFQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbhMxEB1VRajwgLiKQAEjcXnB6sbrvSEhVJWUlKZRVNIqb4vttaWgsBu6iar8AT_BL_BRfAkz2d2UING3vtreXWs8njnjHc8BeIEYwbiY7m1lSnHpAtxSkcy4H2urjaMGOu846ofdE_lpFIw24FdzF4bSKhubuDTUWWHojHwHAwNUR4FG9_30OyfWKPq72lBoVGpxaBfnGLKV7w4-4Pq-FGK_M9zr8ppVgBvpyRmPbJxEGKTotibGHKEylaD1yWTbs4IQQOS0FQ7jjlhLJzwdxkpnoVFt8uYBHYCiyb8mfU9Srf5odBHg-WJJztZGn8fDIAmrmp6-n3g746_fSvSGAgFWKNZ84L-e4CZszfOpWpyryeQvV7d_G27VGJXtVkp1BzZsfheuV6yVi3vgULXYqZrMLSsc6xz__vGTjXOGSJINzgpK3BuX1POxy5nKMzY47vHPhE4pw5oNxrN-Z1i-ZVVF0oIokRsDzPaIK6TOzrsPJ1ci2AewmRe5fQjMSp0E2B44jPdMECfKU4GmfFwRBr5yLXjTCDA1dS1zotSYpBjTkLzTNXm34NVq-LQq4vG_ga9pNVLa3Pg-o-o7CjgrKpOV7iJY9snZRy3YXhuJm9KsdzfrmdZGoUwvVLgFz1fd9CQluuW2mFdjYgSJfoxzWenB5bN-dPnHnsFWd3jUS3sH_cPHcAOXwq8uU27D5uxsbp8gqprpp0tVZvDlqvfOH3k9MGE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbhMxEB1VRdweEFcRKGAkLi9Y2dh7RUKoahNSWqKotFXeFttrS0FhN3QTVfkDfoIf4XP4EmayuylBom99tb27lj2XM97xHIAXiBGMi-neVqYU912AKhX5GZextto4aqDzjk-DsH_sfxwFow341dyFobTKxiYuDXVWGDojb2NggOIo0Oi2XZ0WMdztvZ9-58QgRX9aGzqNSkT27eIMw7fy3d4u7vVLIXrdo50-rxkGuPE9f8YjGycRBiy6o4k9R6hMJWiJMr_jWUFoIHLaCocxSKx9JzwdxkpnoVEd8uwBHYai-b8SSV9SOlk0Og_2pFgStXXQ__EwSMKqvqeUidcef_1WomcUCLZCseYP__UKN-H6PJ-qxZmaTP5ye73bcKvGq2y7ErA7sGHzu3C1YrBc3AOHYsZO1GRuWeFY9_D3j59snDNElWx4WlAS37ikng99zlSeseHhAf9MSJWyrdlwPBt0j8q3rKpOWhA9cmOM2Q7xhtSZevfh-FIW9gFs5kVuHwKzvk4CbA8cxn4miBPlqUBTbq4IA6lcC940C5iauq450WtMUoxvaL3TtfVuwavV8GlV0ON_A1_TbqSk6Pg-o-r7CjgrKpmVbiNwluT4oxZsrY1EBTXr3c1-prWBKNNzcW7B81U3PUlJb7kt5tWYGAGjjHEuKzm4eNaPLv7YM7iGWpMe7A32H8MN3AlZ3avcgs3Z6dw-QYA100-Xkszgy2Wrzh_TKDSc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Value+of+ER%E2%88%9D+in+the+Prognosis+of+GH-+and+PRL-Secreting+PitNETs%3A+Clinicopathological+Correlations&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Dumitriu-Stan%2C+Roxana-Ioana&rft.au=Burcea%2C+Iulia-Florentina&rft.au=Nastase%2C+Valeria+Nicoleta&rft.au=Ceau%C8%99u%2C+Raluca+Amalia&rft.date=2023-11-01&rft.issn=1422-0067&rft.eissn=1422-0067&rft.volume=24&rft.issue=22&rft_id=info:doi/10.3390%2Fijms242216162&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon